SE9604731D0 - A component of intercellular junctions in the endothelium - Google Patents

A component of intercellular junctions in the endothelium

Info

Publication number
SE9604731D0
SE9604731D0 SE9604731A SE9604731A SE9604731D0 SE 9604731 D0 SE9604731 D0 SE 9604731D0 SE 9604731 A SE9604731 A SE 9604731A SE 9604731 A SE9604731 A SE 9604731A SE 9604731 D0 SE9604731 D0 SE 9604731D0
Authority
SE
Sweden
Prior art keywords
endothelium
component
intercellular junctions
cadherin molecule
antibodies
Prior art date
Application number
SE9604731A
Other languages
Swedish (sv)
Inventor
Elisabetta Dejana
Paola Telo
Original Assignee
Tamas Bartfai Konsulting Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tamas Bartfai Konsulting Ab filed Critical Tamas Bartfai Konsulting Ab
Priority to SE9604731A priority Critical patent/SE9604731D0/en
Publication of SE9604731D0 publication Critical patent/SE9604731D0/en
Priority to PCT/US1997/020006 priority patent/WO1998025946A1/en
Priority to JP52665598A priority patent/JP2002512505A/en
Priority to CA002245956A priority patent/CA2245956A1/en
Priority to EP97948160A priority patent/EP0889900A1/en
Priority to AU54283/98A priority patent/AU5428398A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A new VE-cadherin molecule is provided. Monoclonal antibodies that specifically bind to and neutralize an extracellular domain of a VE-cadherin molecule are provided. In vitro and in vivo methods of using these antibodies are also provided.
SE9604731A 1996-12-12 1996-12-20 A component of intercellular junctions in the endothelium SE9604731D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE9604731A SE9604731D0 (en) 1996-12-20 1996-12-20 A component of intercellular junctions in the endothelium
PCT/US1997/020006 WO1998025946A1 (en) 1996-12-12 1997-11-05 Monoclonal antibodies specific to endothelial cell cadherins and uses thereof
JP52665598A JP2002512505A (en) 1996-12-20 1997-11-05 Monoclonal antibodies specific for endothelial cell cadherins and their uses
CA002245956A CA2245956A1 (en) 1996-12-20 1997-11-05 Monoclonal antibodies specific to endothelial cell cadherins and uses thereof
EP97948160A EP0889900A1 (en) 1996-12-12 1997-11-05 Monoclonal antibodies specific to endothelial cell cadherins and uses thereof
AU54283/98A AU5428398A (en) 1996-12-12 1997-11-05 Monoclonal antibodies specific to endothelial cell cadherins and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604731A SE9604731D0 (en) 1996-12-20 1996-12-20 A component of intercellular junctions in the endothelium

Publications (1)

Publication Number Publication Date
SE9604731D0 true SE9604731D0 (en) 1996-12-20

Family

ID=20405090

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604731A SE9604731D0 (en) 1996-12-12 1996-12-20 A component of intercellular junctions in the endothelium

Country Status (6)

Country Link
EP (1) EP0889900A1 (en)
JP (1) JP2002512505A (en)
AU (1) AU5428398A (en)
CA (1) CA2245956A1 (en)
SE (1) SE9604731D0 (en)
WO (1) WO1998025946A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638911B1 (en) 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
JP2003520254A (en) * 2000-01-19 2003-07-02 エス． ジル，パーカッシュ Methods and compositions relating to antisense VEGF oligonucleotides
WO2001055214A2 (en) * 2000-01-25 2001-08-02 Novartis Ag Asthma-associated gene
US20020081599A1 (en) * 2000-04-18 2002-06-27 Curtis Rory A. J. 57809 and 57798, novel human cadherin molecules and uses therefor
GB0010630D0 (en) * 2000-05-04 2000-06-21 Univ Wales Medicine Sequence
WO2002099140A1 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. GLRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003229627A1 (en) * 2002-04-08 2003-10-20 Max-Planck-Gesellschaft Zur Ve-ptp as regulator of ve-cadherin mediated processes or disorders
EP1560850A2 (en) 2002-11-14 2005-08-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
US20040167076A1 (en) 2003-02-14 2004-08-26 Stamer W. Daniel Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells
UA95775C2 (en) 2005-04-26 2011-09-12 Пфайзер Инк. Antibody that specifically binds to p-cadherin
US20080194467A1 (en) * 2006-09-27 2008-08-14 Adherex Technologies, Inc. Cancer treatment methods using cadherin antagonists in combination with anticancer agents
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2012136820A1 (en) 2011-04-08 2012-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-ve-cadherin autoantibodies as a biomarker of vascular alterations associated with disorders
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
CN117479957A (en) * 2021-07-19 2024-01-30 卫材R&D管理有限公司 Biomarkers for therapies comprising angiogenesis inhibitors

Also Published As

Publication number Publication date
WO1998025946A1 (en) 1998-06-18
CA2245956A1 (en) 1998-06-18
AU5428398A (en) 1998-07-03
JP2002512505A (en) 2002-04-23
EP0889900A1 (en) 1999-01-13

Similar Documents

Publication Publication Date Title
SE9604731D0 (en) A component of intercellular junctions in the endothelium
EA199801043A1 (en) ANTIBODIES AGAINST ED-B DOMAIN IN FIBRONECTIN, THEIR DESIGN AND USE
YU28503A (en) Humanized anti-lt-betha-r antibodies
EP0741748A4 (en) Monoclonal antibodies specific to vegf receptors and uses thereof
DE60334364D1 (en) TREATMENT PROCEDURE USING ANTI-CD22 ANTIBODIES
DK0724456T3 (en) CD40 antibodies
MY109957A (en) Improved antibodies to plasmodium falciparum
TR199801390T2 (en) Anticoagulants to be used in the treatment of thrombosis
ES2151277T3 (en) COMPOSITIONS INCLUDING CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND TAXOTERE.
DE69433087D1 (en) ANTI-CD3 ANTIBODY-AMINODEXTRAN CONJUGATES FOR INDUCTION OF T CELL ACTIVATION AND PROPAGATION
NO993739L (en) Diesel additive to improve cetane, lubricity and stability
CY2008003I1 (en) HUMAN MONOCLONAL ANTIBODIES TO EPITERNAL GROWTH FACTOR RECEPTOR
ES2110230T3 (en) RAPAMICINE TEST.
DE69309487T2 (en) PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS
ATE400289T1 (en) USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR 2 (VEGF-2)
DE69128543T2 (en) MONOCLONAL ANTIBODIES OF THE MOUSE
HUP0101151A3 (en) Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbetha6-integrin attachment to fibnronectin
EA200400930A1 (en) BLOCKING MONOCLONAL ANTIBODY TO VLA-1 OR ITS USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
EA200200974A1 (en) MONOCLONAL ANTIBODIES TO THE HUMAN LDL RECEPTOR, THEIR RECEIVING AND APPLICATION
ATE206621T1 (en) IL-8 ANTAGONISTS FOR THE TREATMENT OF ASTHMA
DE60042941D1 (en) USE OF ANTI-CD3 MONOCLONAL ANTIBODIES AND IL-5 FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DK0912612T3 (en) Simplified preparation of bispecific antibody fragments
SE0002835D0 (en) Method and kit for production of monoclonal antibodies
DE69409961D1 (en) TRIARYLETHYLENE DERIVATIVES FOR THERAPEUTIC USE
DE69324038T2 (en) ANISOTROPE COMPOSITE FOR HYPER FREQUENCIES